Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens

Researchers Present Data at Breast Cancer Symposium Showing MammaPrint/BluePrint Can Identify Women Who Benefit from Chemotherapy and Targeted Dual Anti-HER2 Drug Treatment Before Surgery IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia’s MammaPrint® and BluePrint® tests provide new insights that may provide many … Continued

Agendia Board of Directors Appoints Mark R. Straley as New CEO

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer.  He succeeds Jan Egberts, M.D, who took … Continued

Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO

Publication Name: Press Release

IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular diagnostic company, today announced the appointment of life science industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He replaces David Macdonald, who has left the company … Continued